GLP-1 and Autoimmune Disease Guide

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were developed for diabetes and obesity — but growing evidence shows their anti-inflammatory properties extend to autoimmune conditions.

GLP-1 receptors are expressed on dendritic cells, macrophages, T-cells, intestinal epithelium, and skin keratinocytes, making GLP-1 therapy an emerging immune modulator beyond its metabolic effects.

Semaglutide has demonstrated anti-inflammatory effects through multiple mechanisms: direct GLP-1 receptor activation on dendritic cells and macrophages (shifting toward anti-inflammatory M2 phenotype), IL-6 and TNF-alpha reduction, and adipose-derived inflammatory cytokine reduction from weight loss.

Early observational data suggest improvements in IBD (particularly UC), psoriasis severity scores, and rheumatoid arthritis DAS28 scores in obese patients.

GLP-1 receptors are expressed on intestinal epithelial cells, enteric neurons, and gut immune cells.

GLP-1 receptor agonists reduce intestinal inflammation via NF-κB suppression, improve gut motility, and may restore intestinal barrier integrity. A dedicated Phase 2 trial (SEMA-IBD) is currently ongoing.

Off-label GLP-1 use for UC is being explored in academic centers.

Multiple retrospective analyses have noted psoriasis severity reduction in patients on GLP-1 agonists.

The mechanism involves both direct anti-inflammatory effects (GLP-1R on keratinocytes and dermal immune cells) and weight-loss-mediated reduction in adipokines that drive psoriatic inflammation. PASI score improvements of 30–50% have been reported in obese psoriatic patients on semaglutide or tirzepatide.